Ahaviah Glaser, director of the Prescription Access Litigation project, says that consumers are tired of waiting for legislators to make drugs more accessible, and have simply taken matters into their own hands.

ECONOMIST: Pharmaceuticals: Courting trouble | The

According to Stephen Rosenfeld, a lawyer with the Prescription Access Litigation Project, which has launched a class-action suit against AstraZeneca and Barr Laboratories over Tamoxifen, an anti-cancer drug, delays to generic drugs mean that 42m Americans who lack health insurance pay a high price, and may not get essential medicines at all.

ECONOMIST: Prescription drugs